Founding father recognised for outstanding cancer care
15 November 2017
A founding father of Melanoma Institute Australia, Professor William McCarthy AM, has been recognised for his contributions to cancer care by being awarded the Tom Reeve Award for Outstanding Contributions to Cancer Care at the Clinical Oncology Society of Australia dinner last night.
The award is given annually to a national leader who has made a significant contribution over a long period of time to cancer care through research, clinical leadership and community service.
One nominee wrote: “There is no questioning Professor McCarthy’s contribution to the improvement of the care of patients with cancer and in particular patients with melanoma in his home state of New South Wales, in Australia and internationally…. in the roles of clinician, researcher, teacher and contributor to national forums related to the disease.”
The former Executive Director of the Sydney Melanoma Unit (now known as Melanoma Institute Australia) has led the world in melanoma education, general medical education and melanoma surgery.
Professor McCarthy graduated from The University of Sydney’s Faculty of Medicine in 1958 and trained in surgery at St Vincent’s Hospital Sydney. He then obtained a Master’s Degree in Medical Education at the University of Illinois, Chicago, and worked in various surgical registrar postings in the United Kingdom.
Returning to Sydney in 1968, Professor McCarthy was appointed a Lecturer in Surgery at The University of Sydney and a Visiting Medical Officer at Sydney Hospital where he worked with Professor Gerry Milton in the Sydney Melanoma Unit.
His academic achievements include some 180 peer‐reviewed publications over a span of 50 years. He was promoted steadily in the University, becoming Professor of Surgery (Melanoma and Skin Oncology) in 1990; a post he held until his retirement in 2005 when he was appointed Professor Emeritus.
His contributions were recognised by appointment as a Member (AM) of the Order of Australia in 1993 and receipt of the World Health Organisation Melanoma Award in 2001. He served on the Clinical Oncology Society of Australia Council and was President in 1992 and 1993.
Australian researchers have for the first time identified specific cells and receptors in the immune system which predict how a patient will respond to treatment with immunotherapies, potentially paving the way for the development of personalised therapy for all cancer patients.
Melanoma March is thrilled to introduce Ricky as our official Principal Partner for 2019!
World record holder, Olympian and Australian swimming champion Cate Campbell has been announced as National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.
MIA's expertise was essential to a recent Nature publication spearheaded by Perth’s Telethon Kids Institute and The University of Melbourne.
MIA is delighted to be hosting the MD Anderson pathologist on his first ever trip to Australia.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for dabrafenib and trametinib.
Three students from Arden Anglican School in Epping have won Melanoma Institute Australia’s (MIA) inaugural SunSafe Student Ambassador Award.
Mark Whittaker’s ‘Here comes the sun; Defending our summer rays’ (GW 24 Nov) clouds the sun-safe message – which could have disastrous consequences.
Professor Georgina Long is among only 12 researchers from the University of Sydney to be named in the 2018 Highly Cited Researchers List.
‘Wearing sunscreen should be as automatic as wearing a seatbelt. Both are potential life savers.’
The Poche Centre to host 3D total-body imaging system as part of world-first initiative to save lives from melanoma
A prestigious $10 million Australian Cancer Research Foundation grant has been awarded to ACEMID, an initiative that aims to use 3D total-body imaging and a remote medicine network to improve the detection and diagnosis of early-stage melanoma.
Professor Georgina Long and Professor Richard Scolyer have been recognised as world leaders in melanoma research for their ground-breaking work that has changed the diagnosis and treatment landscape of melanoma world-wide, and tripled the life-expectancy of advanced melanoma patients.
Leading researchers from Melanoma Institute Australia have taken out the top accolades at the NSW Premier’s Awards for Outstanding Cancer Research.
An impressive contingent of female delegates from Melanoma Institute Australia have presented findings across the whole spectrum of melanoma research at the Society for Melanoma Research 2018 Congress in Manchester, England.
Over 800 researchers and clinicians from around the world were welcomed to Manchester for the 15th International Congress of the Society for Melanoma Research (SMR). Melanoma Institute Australia (MIA) has again sent an impressive number of delegates to present both oral presentations and posters with the latest in translational research.
Professor Georgina Long makes history as the first woman and first Australian to lead the Society for Melanoma Research
Professor Georgina Long makes history as the first woman and first Australian to lead the world’s most prestigious international melanoma research association.
Two publications co-edited by MIA Co-Medical Director Professor Richard Scolyer are now available to healthcare professionals. They aim to provide assistance in the care and management of patients with skin cancer, including melanoma.
Melanoma Institute Australia has introduced a new educational program to teach teenagers about the dangers of melanoma and the importance of sun safety.
"International collaboration remains the key to ensuring this pioneering research continues so we can increase survival rates for advanced melanoma patients and move us closer to achieving our goal of zero deaths from melanoma," says Professor Georgina Long, of the clinical trial results presented at ESMO 2018.
Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.